America's Vaccine Trust Problem

Executive summary

Vaccine fatigue is reshaping American public health in real time — and a new survey of 254 U.S. adults shows the shift is more nuanced, and more consequential, than a simple pro- versus anti-vaccine divide.

Seven in ten respondents (70.1%) still view vaccines at least somewhat positively. But that headline number masks a deeper story: broad support is conditional, trust in health authorities is eroding, and the COVID-19 era has left a lasting mark on how people weigh vaccination decisions. Only 30.3% hold unambiguously positive views. Nearly one in three respondents holds negative views of vaccines overall.

The practical fallout is already visible. As of fall 2024, just 17.9% of U.S. adults had received a COVID vaccine for the current season. Kindergarten MMR coverage has dropped below the 95% herd immunity threshold. And the U.S. is now battling its worst measles outbreak since 1991, with more than 1,500 cases in 2026 alone.

This survey captures the attitudinal engine behind those numbers — and points to what public health communicators, policymakers, and employers need to understand before the next vaccine rollout.

Context

The COVID-19 pandemic forced vaccines into the center of American political life in a way that no health event had in a generation. Mandates, boosters, and breakthrough infections dominated headlines for years. Now, with the acute phase of the pandemic receding, a new and harder-to-measure problem has taken hold: a broad, slow-burning disengagement from vaccines as a category — not just COVID shots.

Public health researchers have named this dynamic 'vaccine fatigue,' defined as the exhaustion and skepticism that builds when people are overwhelmed by repeated, sometimes contradictory vaccine messaging. A peer-reviewed study published in the Journal of Health Communication found that message fatigue independently suppressed COVID booster uptake and intentions in the U.S., above and beyond standard predictors like perceived risk or convenience. A 23-country Nature Medicine study published in 2023 found that COVID booster intent dropped 16 percentage points in a single year globally, and nearly one in four adults worldwide reported being less willing to vaccinate against non-COVID diseases as a result of their pandemic experience.

This survey was conducted to measure where U.S. adults actually stand — not on vaccination ideology, but on the practical, emotional, and structural factors shaping their decisions. With 254 respondents answering four questions — including two open-ended prompts on mandates and vaccine fatigue — the study captures both the quantitative distribution of vaccine attitudes and the qualitative texture of how people are reasoning through them.

The timing is urgent. The federal Bridge Access Program that covered COVID vaccines for uninsured adults has expired, leaving shots costing up to $200 out of pocket. The CDC's Advisory Committee on Immunization Practices was overhauled in 2025, with all incumbent members replaced by vaccine skeptics. Kindergarten MMR coverage has fallen below the 95% threshold needed for herd immunity. Against that backdrop, understanding where hesitancy begins — and where it can be interrupted — has direct consequences for the next outbreak, the next vaccine rollout, and the next policy fight over mandates.

Findings

Support Is Broad but Brittle

On the surface, American vaccine support looks healthy: 70.1% of respondents view vaccines at least somewhat positively. But dig one layer deeper and the foundation shows cracks. The largest single response category — chosen by 39.8% of respondents — is 'somewhat positively, there are upsides but downsides need to be considered.' That is conditional support, not confident endorsement.

Only 30.3% chose the unambiguously positive option. Meanwhile, 16.1% view vaccines somewhat negatively and 13.8% view them very negatively — meaning nearly three in ten respondents are net skeptics. That split maps closely onto KFF polling, which found that just 56% of U.S. adults are 'somewhat confident' COVID-19 vaccines are safe, with confidence among Republicans collapsing to 30%.

The picture that emerges is not a population that has rejected vaccines, but one that has become a tougher audience — requiring clearer evidence, greater trust, and stronger justification to act.

Disease Severity Rules the Decision

When asked what would give them pause before taking a vaccine, respondents ranked their concerns clearly: 33.3% said they would hesitate if the vaccine does not protect against a serious disease — the single most common barrier, outpacing every other factor by a wide margin.

Cost and coverage came second, cited by 22.1% of respondents. Travel inconvenience was flagged by 18.5%, and paperwork burden by 17.2%. Only 8.9% said none of these factors would give them pause — meaning more than nine in ten respondents have at least one structural or attitudinal barrier to vaccination.

This hierarchy has direct implications for public health strategy. Modeling research published in Advances in Continuous and Discrete Models found that under a 'Severe Illness Prevention' framework — which mirrors how these respondents actually think — reducing vaccine costs is a far more powerful lever for boosting uptake than improving vaccine effectiveness. In other words, the barriers respondents named are exactly the ones public health systems are least equipped to address right now, especially as federal subsidies disappear.

Vaccine Fatigue: Real, Recognized, and Consequential

When asked about vaccine fatigue directly, respondents broadly validated the concept. Open-ended responses described the post-COVID information environment as exhausting, contradictory, and trust-destroying. The sentiment analysis of those responses found a statistically significant lean toward viewing vaccine fatigue as a genuine and significant issue (p < 0.0001), not an exaggerated or manufactured one.

Respondents described specific mechanisms: conflicting guidance from health authorities, distrust rooted in the speed of COVID vaccine development, and a growing sense that vaccine messaging serves institutional interests rather than individual health. The speed of development was a particularly high-signal concern — open-ended responses repeatedly referenced 'fast-tracked' and 'not well tested,' and the dimension analysis found a statistically significant lean toward the view that rapid development compromises safety (mean score +0.28 on a −1 to +1 scale, p < 0.0001).

This is not a fringe view. Qualitative research published in Human Vaccines & Immunotherapeutics found that rapid development timelines were widely perceived as implausible and inherently suspicious — a key barrier to acceptance that standard pro-vaccine messaging fails to address.

Mandates: Targeted Yes, Universal No

On government and company vaccine mandates, respondents lean decisively toward individual choice and away from broad mandates — but the opposition is not absolute. The mandate dimension analysis showed respondents prefer mandates limited to high-risk or specific workplace settings (mean −0.37 on a scope scale, p < 0.0001), rather than universal requirements. Hospitals, nursing homes, and schools surfaced repeatedly in open-ended responses as contexts where mandates feel more defensible.

The evidence threshold matters enormously. Respondents show a statistically significant preference for mandates only after long-term safety is proven (mean −0.29), and they modestly favor private companies over government as the appropriate authority for vaccine requirements (mean −0.24). When it comes to vaccine type, respondents lean toward limiting any mandate to vaccines with established long-term safety records — a direct rebuke to emergency-use frameworks.

The practical implication: sweeping mandates are likely to backfire with this population. Targeted, evidence-anchored, employer-level policies in high-risk settings are the approach most likely to gain compliance without triggering the autonomy backlash that drives deeper disengagement.

Conclusion

The U.S. is not in a post-vaccine era — but it is in a post-trust era. This survey captures a public that still believes in vaccines as a concept, but has accumulated enough disappointment, confusion, and institutional skepticism to make that belief conditional and context-dependent. Seventy percent say they view vaccines positively, but that number means little if the conditions for acting on it — a serious disease threat, affordable access, and trustworthy guidance — are not met.

The warning signs are already flashing. Measles cases are at a 35-year high. Childhood vaccination coverage has fallen below the herd immunity floor. COVID vaccine uptake for the 2024 season reached barely 18% of adults. These are not abstract projections — they are the downstream cost of the attitudes this study documents.

What to watch next: The dismantling of the CDC's vaccine advisory infrastructure, the end of federal vaccine subsidies, and the political weaponization of vaccine messaging are all likely to deepen the trust deficit respondents described. Public health communicators who lead with disease severity, meet people where they are on cost and access, and resist sweeping mandates in favor of targeted, evidence-grounded policies will find more traction than those who don't. The window to rebuild that trust is narrowing.